Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$0.44 - $1.22 $192,192 - $532,896
436,800 New
436,800 $301,000
Q3 2019

Nov 07, 2019

SELL
$12.03 - $19.94 $162,669 - $269,628
-13,522 Closed
0 $0
Q2 2019

Aug 01, 2019

SELL
$19.05 - $41.04 $704,221 - $1.52 Million
-36,967 Reduced 73.22%
13,522 $272,000
Q1 2019

May 08, 2019

BUY
$28.4 - $41.74 $105,080 - $154,438
3,700 Added 7.91%
50,489 $2.01 Million
Q4 2018

Feb 01, 2019

BUY
$30.9 - $42.97 $40,170 - $55,861
1,300 Added 2.86%
46,789 $1.63 Million
Q3 2018

Nov 01, 2018

BUY
$35.05 - $43.5 $84,120 - $104,400
2,400 Added 5.57%
45,489 $1.88 Million
Q2 2018

Jul 31, 2018

BUY
$35.15 - $51.45 $70,300 - $102,900
2,000 Added 4.87%
43,089 $1.58 Million
Q1 2018

May 11, 2018

BUY
$18.0 - $48.35 $739,602 - $1.99 Million
41,089 New
41,089 $1.6 Million

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.26B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.